SCHEMBL984793

SCHEMBL984793

CC1(c2ccc3[nH]ccc3c2)CCN(Cc2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.49
CYP2D6 P10635 5/20 0.49
SLC6A2 P23975 4/20 0.49
SLC6A4 P31645 4/20 0.49
SLC6A3 Q01959 4/20 0.49
KCNH2 Q12809 1/20 0.48
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
EPHX1 P07099 1/20 0.46
EPHX2 P34913 1/20 0.46
ACHE P22303 1/20 0.44
HTR4 Q13639 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
GAA P10253 1/20 0.43
FAAH O00519 1/20 0.42
MEN1 O00255 1/20 0.40
TSHR P16473 1/20 0.40
DRD2 P14416 2/20 0.40
DRD4 P21917 2/20 0.40
DRD3 P35462 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL984260 0.84 SLC6A2 (0.63) MAPK14CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL984198 0.83 CYP2D6 (0.64) MAPK14CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL983580 0.78 SLC6A2 (0.60) MAPK14CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL681083 0.78 GAA (0.58) CYP2D6KMT2AKDM4ESIGMAR1GAA
SCHEMBL981724 0.78 SLC6A2 (0.47) MAPK14CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL984138 0.78 SLC6A2 (0.66) MAPK14CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL980402 0.77 SLC6A2 (0.63) MAPK14CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL24685361 0.76 GAA (0.48) CYP2D6KMT2AKDM4ESIGMAR1GAA
SCHEMBL24685832 0.76 CCR3 (0.61) KMT2AKDM4ESIGMAR1GAAMEN1
SCHEMBL984635 0.75 CYP2D6 (0.62) MAPK14CYP2D6SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 MAPK14 3957/4885CYP2D6 97/4885SLC6A2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.